359878-47-0

Basic information

• Product Name: N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine
• Synonyms: N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine;4-(4-Fluorobenzylamino)-1-methylpiperidine;N-(4-fluorobenzyl)-1-Methylpiperidin-4-aMine;N-(4-flurobenzyl)-1-methylpiperidin-4-Amine
• CAS NO: 359878-47-0
• Molecular Formula: C₁₃H₁₉FN₂
• Molecular Weight: 222
• EINECS: 1592732-453-0
• Mol File: 359878-47-0.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 305℃
• Flash Point: 138℃
• Appearance: /
• Density: 1.07
• Vapor Pressure: 0.000852mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 9.38±0.20(Predicted)
• CAS DataBase Reference: N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine(359878-47-0)
• EPA Substance Registry System: N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine(359878-47-0)

Safety Data

• Hazardous Substances Data: 359878-47-0(Hazardous Substances Data)

Usage

Description

N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine is a chemical compound belonging to the class of piperidine derivatives. It is characterized by its molecular structure that includes a fluorophenyl group attached to the nitrogen atom, a methyl group on the first carbon, and a piperidine ring. N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine is known for its potential applications in the pharmaceutical industry due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure allows it to serve as a building block in the development of new medications, particularly those targeting the central nervous system.
As a pharmaceutical intermediate, N-[(4-Fluorophenyl)methyl]-1-methyl-4-piperidinamine is utilized for the following reasons:
1. Its fluorophenyl group can potentially enhance the lipophilicity and bioavailability of the final drug product, improving its absorption and distribution within the body.
2. The presence of the methyl group on the first carbon can influence the compound's metabolic stability and pharmacokinetic properties, which are crucial factors in drug design.
3. The piperidine ring provides a versatile scaffold for further chemical modifications, allowing the development of a range of drug candidates with different therapeutic applications.

InChI:InChI=1/C13H19FN2/c1-16-8-6-13(7-9-16)15-10-11-2-4-12(14)5-3-11/h2-5,13,15H,6-10H2,1H3

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 140-75-0 para-fluorobenzylamine 
• 41838-46-4 4-Amino-1-methylpiperidine 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 706779-91-1 N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′-(4-(2-methylpropyloxyl)phenylmethyl)carbamide 
• 1080491-34-4 1-(4-fluorobenzyl)-3-(4-(1,1-d2-isobutoxy)benzyl)-1-(1-methylpiperidin-4-yl)urea 
• 1134815-56-7 N-((4-fluorophenyl)methyl)-N-(1-methylpiperidin-4-yl)-N'-((4-methoxyphenyl)methyl)carbamide 
• 1246458-38-7 3-(4-(benzyloxy)-2-methoxybenzyl)-1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)urea 
• 1246458-14-9 methyl 3-(4-((3-(4-fluorobenzyl)-3-(1-methylpiperidin-4-yl)ureido)methyl)phenoxy)-2-methylpropanoate 
• 1246458-36-5 3-(2-(benzyloxy)-4-methoxybenzyl)-1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)urea 
• 1246458-29-6 1-(4-fluorobenzyl)-3-(3-benzyloxy-4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea 
• 1246458-13-8 1-(4-fluorobenzyl)-3-(4-(2-methylallyloxy)benzyl)-1-(1-methylpiperidin-4-yl)urea 
• 706782-28-7 Pimavanserin tartrate 
• 1080491-31-1 N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartaric acid 

Relevant articles and documents

Novel derivatives of urea and use thereof

The present invention relates to a novel urea derivative compound and 5HT thereof. 2A The present invention relates to the use of antagonists as antagonists for the prevention or treatment of neuropsychiatric disorders, degenerative brain diseases, propagated disorders and/or metabolic diseases.

Application of pimavanserin in preparation of antitumor drugs

The invention relates to application of pimavanserin in preparation of antitumor drugs, belongs to the technical field of medicines, and particularly relates to novel application of pimavanserin in preparation of antitumor drugs. The structural formula of the pimavanserin is shown in the formula I. The biological activity test of the compound shows that the compound has antitumor activity and is a novel antitumor drug.

PROCESS FOR THE MANUFACTURING OF PIMAVANSERIN

The present invention relates to a new process for manufacturing 1-(4-fluorobenzyl)-3-(4-iso-butoxyphenyl)-1-(1-methylpiperidin-4-yl)urea, with the INN name pimavanserin, and its hemitartrate salt.